Sorafenib may improve response rate and progression-free survival (PFS) duration in patients with iodine refractory thyroid cancer

Source: Inpharma, Volume 1, Number 1647, 2008-07-19 , pp. 6-6(1)

Publisher: Adis International

Keywords: Sorafenib, therapeutic use; Thyroid-cancer, treatment

Document Type: Research article

Publication date: 2008-01-01

• In this: publication
• By this: publisher
• In this Subject: Pharmacology

Website © Publishing Technology. Article copyright remains with the publisher, society or author(s) as specified within the article.

• Terms and conditions
• Privacy policy
• Information for advertisers